Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorChangi General Hospital
About this trial
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.
Eligibility criteria
Qualifiers
Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.
Willing to undergo subtype testing with adrenal vein sampling and/or molecular imaging (Positron Emission Tomography/Computed Tomography, PET/CT).
Keen for surgical treatment if shown to have unilateral primary aldosteronism.
Disqualifiers
Inability to provide written informed consent.
Trial design
Treatments tested in this trial
- Hybrid hormones
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
Changi General Hospital
Lead sponsor
Singapore General Hospital
Collaborator
Sengkang General Hospital
Collaborator
National University Hospital, Singapore
Collaborator
Source ClinicalTrials.gov